Stockwatch: Its about the data
This article was originally published in Scrip
Executive Summary
Long-suffering investors in Switzerland's Addex received a welcome boost when the company reported positive phase IIa results for its mGluR5 negative allosteric modulator, dipraglurant for Parkinson’s Disease (PD) (scripintelligence.com, 22 March 2012). The Addex share price jumped over 80% on the announcement, reflecting the relief by many investors that the Addex platform for discovering allosteric modulators may come up with something after a few disappointments.